Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and...

Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy...

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...

Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony SOUTH SAN FRANCISCO, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- California Life Sciences Association (CLSA), the leading voice to drive innovation for California's life sciences sector, today announced...